Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis.

ABSTRACT:

Objective

Autoantibodies can be useful in predicting response to certain treatments in rheumatoid arthritis (RA). We aimed to evaluate initial response to tocilizumab (TCZ) by change in physician and patient-reported outcomes and laboratory parameters in a real-world cohort of patients with RA. We analyzed the data by autoantibody status to determine whether patients with seronegative RA had improved response to tocilizumab when compared to their seropositive counterparts.

Methods

Data from the CORRONA RA registry were analyzed. Patients were included if they were started on TCZ and had data from a follow-up visit 4-8 months after initiation, as well as having information on serologic status. Serologic status was determined by presence of anti-cyclic citrullinated peptide (C

SUBMITTER: Cappelli LC 

PROVIDER: S-EPMC5623175 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature